Aging does not impact safety and efficacy of biologic or targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Egyptian Rheumatology and Rehabilitation, cilt.52, sa.1, 2025 (ESCI, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 52 Sayı: 1
- Basım Tarihi: 2025
- Doi Numarası: 10.1186/s43166-025-00336-2
- Dergi Adı: Egyptian Rheumatology and Rehabilitation
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
- Anahtar Kelimeler: bDMARDs, Elderly, EULAR, HAQ, Rheumatoid arthritis, Safety of DMARDs, Tofacitinib
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: The study compared biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) efficacy and safety in elderly rheumatoid arthritis (RA) patients over a period of 1 year. Results: This retrospective study included 52 RA patients. At baseline elderly patients had longer disease duration, more comorbidities and extraarticular involvement, and previously used conventional synthetic (cs) DMARDs (p < 0.05). A statistically significant change from baseline was observed in the 6th and 12th months regarding Disease Activity Score (DAS-28) and the Health Assessment Questionnaire (HAQ) scores were observed in both groups following treatment with bDMARDs/tsDMARD (p < 0.000). These changes in DAS-28 and HAQ scores were similar in both groups and showed no statistical difference between groups (p = 0.974 and p = 0.578 respectively). Also, no differences were observed between the groups with respect to the percentage of good, moderate or non-responders according to European Alliance of Associations for Rheumatology response criteria. Similarly, no differences were found between groups regarding severe adverse events, drug discontinuation or switch rates. Conclusion: The efficacy and adverse effects of bDMARDs/tsDMARD were similar in elderly and younger RA patients. Both bDMARDs and tsDMARD are efficacious and safe for use in elderly RA patients.